Skip to main content
HCPCS Q5147 · Level II · Part B drug

Q5147: aflibercept-ayyh (Pavblu), HCPCS Level II drug code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for Q5147

Billing unit
1 MG
Inj, aflibercept-ayyh, 1 mg
ASP payment limit
$763.376
October 2026; -5.0% vs July 2026
Practitioner MUE
4
MAI 2
OPPS status
SI G
APC 2068
NCCI exposure
no PTP pairs
Coverage articles
2
12 states

TL;DR

HCPCS Q5147 is the Level II code for Injection, aflibercept-ayyh (pavblu), biosimilar, 1 mg, billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $763.376 per billing unit, down 5.0% from July 2026. The practitioner MUE allows up to 4 units per date of service (MAI 2), so a full 4-unit day is $3,053.50 at the current limit. Under OPPS it carries status indicator G in APC 2068. As a biosimilar it has its own code and ASP; the reference product cannot be billed under this code, and the JZ or JW modifier rules for discarded amounts apply per single-dose vial. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. Other HCPCS codes whose descriptor names aflibercept: J0178 (non-biosimilar aflibercept (Eylea) from Regeneron Pharmaceuticals, Inc). The ASP crosswalk maps 2 NDCs to it, sold as Pavblu by Amgen Inc. 2 Medicare coverage articles list the code across 12 states, including A52451.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for Q5147 at $763.376 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $803.255 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for Q5147
QuarterPayment limitPerCoinsurance
October 2026$763.3761 MG20%
July 2026$803.2551 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 2 NDCs from 1 labeler to Q5147. Report the NDC in the claim's drug segment and bill the number of Q5147 units that equals the quantity administered divided by 1 MG; the last column gives units per full package.

NDCs that crosswalk to Q5147
NDCDrug nameLabelerPackage sizeBilling units / package
55513-0056-01PavbluAmgen Inc0.05 × 12
55513-0065-01PavbluAmgen Inc0.05 × 12

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for Q5147. For practitioners the limit is 4 units per date of service with adjudication indicator 2, a date-of-service policy edit: the limit reflects CMS policy and units above it deny even if split across lines; appeals rarely succeed.

MUE values for Q5147 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services42 Date of Service Edit: PolicyAnatomic Consideration
Facility outpatient hospital42 Date of Service Edit: PolicyAnatomic Consideration
DME supplier42 Date of Service Edit: PolicyAnatomic Consideration

MUE for Q5147 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists Q5147 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check Q5147 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

Q5147 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

2 current Medicare Administrative Contractor articles list Q5147 in their HCPCS tables, covering 12 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing Q5147
ArticleTitleContractor(s)StatesRelated LCD
A52451Billing and Coding: Ranibizumab, Aflibercept and biosimilarsWellpoint FederalCT IL MN NY WIL33394
A53387Billing and Coding: Aflibercept (EYLEA®)Palmetto GBAAL GA NC SC TN VA WV—

Diagnoses Medicare contractors cover for Q5147

One billing and coding article attaches a covered diagnosis list to Q5147: 224 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 15 covered ICD-10-CM codes for Q5147
ICD-10-CMDescription (FY2027)Articles covering
E08.311Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema1 of 1
E08.319Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema1 of 1
E08.3211Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye1 of 1
E08.3212Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye1 of 1
E08.3213Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral1 of 1
E08.3291Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye1 of 1
E08.3292Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye1 of 1
E08.3293Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral1 of 1
E08.3311Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye1 of 1
E08.3312Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye1 of 1
E08.3313Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral1 of 1
E08.3391Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye1 of 1
E08.3392Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye1 of 1
E08.3393Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral1 of 1
E08.3411Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye1 of 1
209 more codes are in the full lists linked below.

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to Q5147 are counted here: a group whose instructions name Q5147, together with any unnamed groups directly after it, read as continuations of those instructions. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to Q5147, by article
ArticleContractorGroups that applyCovered codes for Q5147Full list
A52451Wellpoint Federalgroup 2 applies to Q5147224On LCD L33394
A53387Palmetto GBAno covered diagnosis list0Open the article

Local coverage policies that list Q5147

1 active Local Coverage Determination lists Q5147 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, Q5147 carries status indicator G and is assigned to APC 2068, with a published national unadjusted payment of $763.376. Status G marks pass-through drug payment, which is time-limited.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), Q5147 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $763.38 per 1 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for Q5147 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for Q5147

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS Q5147

What does HCPCS code Q5147 describe?

Q5147 is defined by CMS as "Injection, aflibercept-ayyh (pavblu), biosimilar, 1 mg". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is Q5147 a CPT code?

No. Q5147 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as aflibercept-ayyh (Pavblu); CPT codes are five-character codes maintained by the AMA. On a Part B claim Q5147 reports the drug itself in 1 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for Q5147 in October 2026?

The ASP-based payment limit is $763.376 per 1 MG, with 20% beneficiary coinsurance. The July 2026 limit was $803.255. Commercial payers use their own fee schedules.

How many units of Q5147 can be billed per day?

The practitioner Medically Unlikely Edit is 4 units per date of service with adjudication indicator 2 (Date of Service Edit: Policy). MAI 2 edits are policy limits and are rarely overturned on appeal. CMS cites "Anatomic Consideration" as the rationale.

Which NDCs map to Q5147?

The October 2026 ASP crosswalk lists 2 NDCs from 1 labeler: Pavblu (Amgen Inc). For example NDC 55513-0056-01 (package size 0.05) equals 2 billing units of Q5147.

Does Q5147 have NCCI bundling edits?

No active practitioner PTP pairs list Q5147 as a column-1 or column-2 code in the v323r0 release.

Q5147 vs J0178: what is the difference?

Both are HCPCS Level II codes whose descriptor names aflibercept. What sets J0178 apart: non-biosimilar aflibercept (Eylea) from Regeneron Pharmaceuticals, Inc. Q5147 is billed per 1 mg, limit $763.376, MUE 4; J0178 is billed per 1 mg, limit $722.251, MUE 4. Report the code whose descriptor matches the product and setting in the record.

Which Medicare coverage articles mention Q5147?

2 current Billing and Coding Articles in the Medicare Coverage Database list Q5147, covering 12 states: A52451 (Billing and Coding: Ranibizumab, Aflibercept and biosimilars); A53387 (Billing and Coding: Aflibercept (EYLEA®)).

What diagnosis codes support Q5147?

One Medicare billing and coding article lists 224 covered ICD-10-CM codes for Q5147, for example E08.311 (Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema); E08.319 (Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema); E08.3211 (Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye); E08.3212 (Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye); E08.3213 (Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.